Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
5/28/2024 | $5.00 | Buy | Chardan Capital Markets | |
3/27/2024 | Outperform → Market Perform | Noble Capital Markets | ||
11/20/2023 | $15.00 | Neutral | JP Morgan | |
8/28/2023 | $85.00 → $25.00 | Buy → Neutral | H.C. Wainwright | |
8/8/2023 | $45.00 | Neutral → Overweight | Piper Sandler | |
8/4/2023 | $51.00 | Outperform | SVB Securities | |
7/31/2023 | $33.00 | Underperform → In-line | Evercore ISI | |
6/7/2023 | $53.00 → $46.00 | Underperform → Neutral | Wedbush |
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - iBio, Inc. (0001420720) (Subject)
4 - Direct Digital Holdings, Inc. (0001880613) (Issuer)
4 - Direct Digital Holdings, Inc. (0001880613) (Issuer)
4 - Direct Digital Holdings, Inc. (0001880613) (Issuer)
HOUSTON, Aug. 27, 2024 /PRNewswire/ -- Today, Direct Digital Holdings, Inc. (the "Company") reported that the Company received an additional delinquency notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on August 21, 2024, which indicated that, as a result of the delay in the Company's filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Q2 Form 10-Q") by the applicable due date, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ:NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "The second quarter was a period of consistent execution at Novocure," said Asaf Danziger, Novocure's Chief Executive Officer. "We began the year with three k
Novocure (NASDAQ:NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three and six months ended June 30, 2024, at 8:00 a.m. EDT on Thursday, July 25, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of
Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00
Noble Capital Markets downgraded Direct Digital Holdings from Outperform to Market Perform
JP Morgan resumed coverage of NovoCure with a rating of Neutral and set a new price target of $15.00
8-K - NovoCure Ltd (0001645113) (Filer)
8-K - Direct Digital Holdings, Inc. (0001880613) (Filer)
NT 10-Q - Direct Digital Holdings, Inc. (0001880613) (Filer)
After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of Kristi Sarno as senior vice president, business development. Ms. Sarno brings more than 25 years of business development and strategic experience in the life sciences industry to iBio and will play a key role on the leadership team in establishing the company's corporate strategy and leading business development activities, including overseeing search and evaluation and transaction execution. Before joining iBio, Ms. Sarno held key positions in business development, strategic alliance, program management and research at lead
Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of DirectorsBOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following appointments to the Company's Board of Directors, effective July 11, 2024: Shlomi Nachman, former Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sectorTimothy Scannell, former President and Chief Operating Officer of Stryker"We are excited
Novocure (NASDAQ:NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM) patients at the European Society for Medical Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona, Spain. The results of the real-world analysis suggest higher TTFields therapy device usage is significantly associated with improved survival outcomes in a broad population of ndGBM patients. Novocure's ESMO 2024 Data Presentation Details: Poster #459: Association of Tumor Treating Fields Device Usage with Survival in Newly Diagnosed GBM: A Real-World Analysis of Patients in the US Authors:
After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences. Dr. Brenner will give a virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference, held at the Lotte New York Palace Hotel in New York City, September 9-11, 2024. The presentation will be available on-demand from 7 a.m., Sept. 9, at https://journey.ct.events/view/5a0ac133-a550-4997-9da1-dc0b394219bf and following for 30 days. A replay of the webcast will be
Brookline Capital analyst Kemp Dolliver initiates coverage on iBio (AMEX:IBIO) with a Buy rating and announces Price Target of $3.6.